Format

Send to

Choose Destination
Int J Cardiol. 2012 Feb 9;154(3):362-5. doi: 10.1016/j.ijcard.2011.11.005. Epub 2011 Dec 1.

Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: a post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS).

PMID:
22133469
DOI:
10.1016/j.ijcard.2011.11.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center